openPR Logo
Press release

PARP1 Inhibitor Pipeline, Clinical Trials Studies, Emerging Drugs, Agreements & Collaborations, and Latest News 2023 (Updated)

10-25-2023 11:11 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

PARP1 Inhibitor Pipeline

PARP1 Inhibitor Pipeline

DelveInsight's, "PARP Inhibitors Pipeline Insights, 2023," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in PARP Inhibitors pipeline landscape. It covers the PARP1 Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the PARP1 Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the PARP1 Inhibitor Pipeline Report
• DelveInsight's PARP1 Inhibitor pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for PARP1 Inhibitor treatment.
• The leading companies working in the PARP1 Inhibitor Market include TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others.
• Promising PARP1 Inhibitor Pipeline Therapies in the various stages of development include Iniparib, gemcitabine, cisplatin, paclitaxel, Iniparib (SAR2405550 -BSI-201), JPI-289, CEP-9722, and others.
• July 2023: AstraZeneca announced a study of Phase 1 clinical trials for KU-0059436 (AZD2281)(PARP inhibitor). To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours. To further evaluate the safety and efficacy of KU-0059436 in an expanded cohort of BCRA-enriched population, primarily ovarian cancer patients. A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients with Advanced Tumours.

Request a sample and discover the recent advances in PARP1 Inhibitor Treatment Drugs @ PARP1 Inhibitor Pipeline Report- https://www.delveinsight.com/report-store/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the PARP1 Inhibitor pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, PARP1 Inhibitor NDA approvals (if any), and product development activities comprising the technology, PARP1 Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

PARP1 Inhibitor Overview
PARP is a family of proteins loosely based on structural similarity and function. PARP proteins are composed of two ribose moieties and two phosphates per unit polymer. PARP1 and PARP2 are enzymes involved in a DNA repair pathway for SSBs called BER. The best-known PARP is PARP1.

Find out more about PARP1 Inhibitor Therapeutics Assessment @ PARP1 Inhibitor Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

PARP1 Inhibitor Emerging Drugs Profile
• Pamiparib: BeiGene

PARP1 Inhibitor Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the PARP Inhibitors therapies. The PARP1 Inhibitor companies which have their PARP Inhibitors drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

DelveInsight's PARP1 Inhibitor Pipeline Report covers around 30+ products under different phases of clinical development like-
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Learn more about the emerging PARP1 Inhibitor Pipeline Therapies @ PARP1 Inhibitor Clinical Trials Assessment- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the PARP1 Inhibitor Pipeline Report
• Coverage- Global
• PARP1 Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• PARP1 Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• PARP1 Inhibitor Companies- TESARO, AstraZeneca, Sun BioPharma, Eisai Co, BeiGene, IMPACT Therapeutics, Ribon Therapeutics, and others.
• PARP1 Inhibitor Pipeline Therapies- Iniparib, gemcitabine, cisplatin, paclitaxel, Iniparib (SAR2405550 -BSI-201), JPI-289, CEP-9722, and others.

Dive deep into rich insights for new drugs for PARP1 Inhibitor Treatment, Visit @ PARP1 Inhibitor Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. PARP Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. PARP Inhibitors - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Late Stage Products (Phase III)
9. Pamiparib: BeiGene
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Pre-clinical and Discovery Stage Products
13. Drug Name: Company Name
14. Inactive Products
15. PARP Inhibitors Key Companies
16. PARP Inhibitors Key Products
17. PARP Inhibitors- Unmet Needs
18. PARP Inhibitors- Market Drivers and Barriers
19. PARP Inhibitors- Future Perspectives and Conclusion
20. PARP Inhibitors Analyst Views
21. PARP Inhibitors Key Companies
22. Appendix

For further information on the PARP1 Inhibitor Pipeline therapeutics, reach out to PARP1 Inhibitor Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/parp-inhibitors-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recently Published Most Important Links-
https://jobs.recruitingblogs.com/employers/2384764-delveinsight
http://samus.vforums.co.uk/profile/dennydonesdi
http://supportskin.vforums.co.uk/profile/dennydonesdi
http://wwa.vforums.co.uk/profile/dennydonesdi
http://music.vforums.co.uk/general/2838/delveinsight
http://nuchinuxri.vforums.co.uk/profile/dennydones91021
http://raf.vforums.co.uk/profile/dennydonesdi
http://france.vforums.co.uk/Suggestions/1797/market-research-reports
http://thecir.vforums.co.uk/profile/dennydonesdi
http://lol.vforums.co.uk/profile/dennydonesdi
https://www.openlearning.com/u/havensmith-s2ry19/
https://dennydones9.cgsociety.org/profile
https://www.f6s.com/member/denny-dones
https://www.minecraftforum.net/members/dennydones9?__cf_chl_tk=ljVLvJPBSq9.mVHsoWgwPjJb0A23nSrkftR8IxJ5Wec-1697717482-0-gaNycGzNDTs
https://coderwall.com/p/4tufta/herpes-zoster-market-trends-and-developments-in-2023
https://midi.org/forum/20192-herpes-zoster-market-future-prospects-in-2023
https://tapas.io/ybhardwaj
https://photozou.jp/user/top/3328982
https://b.hatena.ne.jp/entry?url=https%3A%2F%2Fwww.delveinsight.com%2Freport-store%2Fherpes-zoster-market
https://www.thingiverse.com/dennydones9/designs
https://soundcloud.com/dennydones
https://experiment.com/users/dennydones9
https://lichess.org/@/dennydones9
https://www.nicovideo.jp/user/130955053
https://menwiki.men/wiki/Main_Page
https://historydb.date/wiki/2_Bonus_Paling_Penting_di_Agen_Sbobet88_Terpercaya
https://mozillabd.science/wiki/Main_Page
https://championsleage.review/wiki/Main_Page
https://timeoftheworld.date/wiki/Main_Page
https://funsilo.date/wiki/Main_Page
https://opensourcebridge.science/wiki/Main_Page
https://scientific-programs.science/wiki/Main_Page
https://lovewiki.faith/wiki/Main_Page
https://influence.co/dennydones9999
https://www.awwwards.com/dennydones9999/
https://www.producthunt.com/discussions/pharma-competitive-intelligence-tracking-services-navigating-the-pharmaceutical-landscape
https://forum.ngs.ru/profile/3132957/
https://zrzutka.pl/profile/delveinsight-295941
https://sound-social.com/story5059347/healthcare-competitive-intelligence-tracking-services
https://socialmarkz.com/story5419072/healthcare-competitive-intelligence-tracking-services
https://network-373.mn.co/posts/41603294
https://www.hogwartsishere.com/1562170/
https://www.renderosity.com/users/id:1400373
https://hitrecord.org/users/dennydones9999/records
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.atlasobscura.com/users/dennydones1
https://freedomlifestyle.mn.co/posts/41604435
https://socialmediainuk.com/story15310402/healthcare-competitive-intelligence-tracking-services
https://onlinedhan.mn.co/posts/41604571
https://skeleton-girls.mn.co/posts/41716585
https://network-89593.mn.co/posts/41716670
https://shaman-leaders.mn.co/posts/41716806
https://walkinvirtualclinics.mn.co/posts/41716883
https://machineintelligence.mn.co/posts/the-role-of-healthcare-partner-identification-services
https://vjudge.net/user/dennydones9999
https://yizhanverse.mn.co/posts/41717293
https://demo.plushforums.com/profile/18/denny-dones
https://www.sideprojectors.com/user/profile/69119
https://bookmarkstumble.com/story16655285/healthcare-partner-identification-services
https://bookmarkstime.com/story15535182/healthcare-partner-identification-services
http://baigasciedil.vforums.co.uk/profile/dennydones9999
http://weareone.vforums.co.uk/profile/dennydones9999
http://astarsuzuki.vforums.co.uk/profile/dennydones9999
http://proweb.vforums.co.uk/action/view_profile/user/dennydones9999
http://taresources.vforums.co.uk/action/view_profile/user/dennydones9999
http://gothicskin.vforums.co.uk/profile/dennydones9999
http://graphics.vforums.co.uk/profile/dennydones9999
http://clapecasna.vforums.co.uk/profile/dennydones9999
http://freuniontest.vforums.co.uk/profile/dennydones9999
http://whatwentwrong.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://system.vforums.co.uk/profile/dennydones9999
http://upsclan.vforums.co.uk/profile/dennydones999911
http://hairetevi.vforums.co.uk/profile/dennydones9999
http://dog199200test.vforums.co.uk/profile/dennydones999911
http://vfscomp2.vforums.co.uk/profile/dennydones9999
http://gamersgetaway.vforums.co.uk/profile/dennydones9999
http://surreyjobs.vforums.co.uk/profile/dennydones9999
http://support2.vforums.co.uk/profile/dennydones9999
http://swlsupport.vforums.co.uk/profile/dennydones9999
http://slipalimer.vforums.co.uk/profile/dennydones990099
http://art.vforums.co.uk/profile/dennydones990099
http://styles.vforums.co.uk/profile/dennydones990099
http://ghofertech.vforums.co.uk/profile/dennydones990099
http://dcdesign.vforums.co.uk/profile/dennydones990099
http://musicspot.vforums.co.uk/profile/dennydones990099
http://prov.vforums.co.uk/profile/dennydones990099
http://russell.vforums.co.uk/profile/dennydones990099
http://makethemes.vforums.co.uk/profile/dennydones990099
http://famousads.vforums.co.uk/profile/dennydones990099
http://pinkness.vforums.co.uk/profile/dennydones990011
http://elseandrew.vforums.co.uk/profile/dennydones99
http://suigacartsing.vforums.co.uk/profile/dennydones99
http://calanaera.vforums.co.uk/profile/dennydones99
http://legstudios.vforums.co.uk/action/view_profile/user/dennydones99
http://idirectory-old.vforums.co.uk/profile/dennydones99
http://skegness.vforums.co.uk/profile/dennydones99
http://futurexistence.vforums.co.uk/action/view_profile/user/dennydones99
http://codes.vforums.co.uk/profile/dennydones99
http://isgicaflo.vforums.co.uk/profile/dennydones99
http://profewovxi.vforums.co.uk/profile/dennydones99
http://zacsplace.vforums.co.uk/profile/dennydones99
http://sneeznavilas.vforums.co.uk/profile/dennydones99
http://coderspalace.vforums.co.uk/profile/dennydones991199
http://guide.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://deviantrhapsody.vforums.co.uk/profile/dennydones99
http://rs2devolution.vforums.co.uk/action/view_profile/user/dennydones99
http://englishporcelain.vforums.co.uk/profile/dennydones99
https://scratchgram-2nd-instagram2.mn.co/posts/navigating-the-healthcare-landscape-with-competitive-intelligence-tracking-services
https://network-84066.mn.co/posts/42686849
https://www.canadavideocompanies.ca/author/dennydones1/
https://monvelli.mn.co/posts/42687788
https://fishjines.mn.co/posts/42688039
https://diecast64.mn.co/posts/42688112
https://mighty-men.mn.co/posts/42688183
https://team-clo.mn.co/posts/unveiling-the-power-of-healthcare-competitive-intelligence-tracking-services
https://stackoverflow.com/users/22614429/denny-dones?tab=profile
https://waarnemingen.be/users/791405/
https://keywebco.mn.co/posts/healthcare-competitive-intelligence-tracking-services-unveiling-the-future-of-healthcare-strategy

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PARP1 Inhibitor Pipeline, Clinical Trials Studies, Emerging Drugs, Agreements & Collaborations, and Latest News 2023 (Updated) here

News-ID: 3262099 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for PARP

PARP Inhibitor Biomarkers Market Size to Expand Lucratively by 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global PARP Inhibitor Biomarkers Market - (By Product (Kits, Assays), By Services (BRCA 1 & 2 Testing, HRD Testing, HRR Testing, Others), By Application (Breast Cancer, Ovarian Cancer, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global PARP Inhibitor Biomarkers Market is valued at US$ 879.8
Parp Inhibitors Market Driven by Demand for Immersive Technologies Across Indust …
Global Parp Inhibitors Market Impact of AI and Automation The PARP inhibitors market has seen remarkable growth in recent years, primarily driven by advances in cancer treatment and the increasing prevalence of cancer globally. These inhibitors, which block the enzyme poly (ADP-ribose) polymerase (PARP), are proving to be highly effective in targeting specific cancer cells, especially in cancers with DNA repair deficiencies like ovarian, breast, and prostate cancers. The approval of
China Market Analysis of PARP Inhibitors: Growth Opportunities
Global PARP Inhibitors Market: Introduction A PARP (poly ADP-ribose polymerase) inhibitor is a substance that blocks PARP enzyme in the cell. DNA damage occurs during cancer. Blocking of PARP helps the cancer cells in repairing their damaged part of DNA. Read Report Overview - https://www.transparencymarketresearch.com/parp-inhibitors-market.html Global PARP Inhibitors Market: Competition Landscape Key players operating in the global PARP inhibitors market are AstraZeneca, Tesaro, AbbVie Inc., Medivation, and Clovis Oncology. The global market is
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
PARP Inhibitors Market Dynamics, Segments, Size and Demand, 2017 - 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
Global PARP Inhibitor Market: Size, Trends And Forecasts (2016-2020)
Scope of the Report The report titled Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020) provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. The report analyses the global Lynparza market in detail along with the regional analysis as